These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34901391)

  • 61. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
    Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
    Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
    Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
    Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
    Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
    Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative proteomic analysis of human malignant ascitic fluids for the development of gastric cancer biomarkers.
    Jin J; Son M; Kim H; Kim H; Kong SH; Kim HK; Kim Y; Han D
    Clin Biochem; 2018 Jun; 56():55-61. PubMed ID: 29654727
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognosis of ovarian cancer is associated with effector memory CD8
    Lieber S; Reinartz S; Raifer H; Finkernagel F; Dreyer T; Bronger H; Jansen JM; Wagner U; Worzfeld T; Müller R; Huber M
    Oncoimmunology; 2018; 7(5):e1424672. PubMed ID: 29721385
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
    Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
    Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
    Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
    BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.
    Kuryk L; Møller AW; Garofalo M; Cerullo V; Pesonen S; Alemany R; Jaderberg M
    J Med Virol; 2018 Oct; 90(10):1669-1673. PubMed ID: 29797583
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Normalization of the ovarian cancer microenvironment by SPARC.
    Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
    Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
    Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
    Front Immunol; 2019; 10():1273. PubMed ID: 31214202
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.
    Ahmed N; Stenvers KL
    Front Oncol; 2013 Sep; 3():256. PubMed ID: 24093089
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 74. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
    Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
    PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PHD finger protein 20-like protein 1 (PHF20L1) in ovarian cancer: from its overexpression in tissue to its upregulation by the ascites microenvironment.
    Alberto-Aguilar DR; Hernández-Ramírez VI; Osorio-Trujillo JC; Gallardo-Rincón D; Toledo-Leyva A; Talamás-Rohana P
    Cancer Cell Int; 2022 Jan; 22(1):6. PubMed ID: 34991589
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Oncolytic adenovirus for treatment of malignant ascites.
    Hemminki A; Heiniö C
    Mol Ther Oncolytics; 2022 Sep; 26():302-303. PubMed ID: 36032634
    [No Abstract]   [Full Text] [Related]  

  • 78. Corrigendum: Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites.
    Hrvat A; Benders S; Kimmig R; Brandau S; Mallmann-Gottschalk N
    Front Immunol; 2024; 15():1420991. PubMed ID: 38742114
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An oncolytic adenovirus co-expressing a bi-specific T cell engager and IL-2 for the treatment of ovarian cancer.
    Ayele K; Wakimoto H; Saha D
    Mol Ther; 2024 Sep; 32(9):2810-2813. PubMed ID: 39178849
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.